ArticleCancers2023
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study.
Full text read
In one paragraph
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Postacute Sequelae Following Omicron COVID-19 in Patients With Cancer.JAMA network open · 2026Article
- Dried Blood-Rumen Content Mixtures as Sustainable Poultry Feed: A Review on Nutritional, Economic, and Environmental Potential.Food science & nutrition · 2025Review
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.Nature communications · 2024Article
- Outcomes and Patterns of Evolution of Patients with Hematological Malignancies during the COVID-19 Pandemic: A Nationwide Study (2020-2022).Journal of clinical medicine · 2024Article
- SARS-CoV-2-Specific T Lymphocytes Analysis in mRNA-Vaccinated Patients with B-Cell Lymphoid Malignancies on Active Treatment.Vaccines · 2024Article
- The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody.BMC infectious diseases · 2024Article
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.medRxiv : the preprint server for health sciences · 2024Article
- Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.Clinical and experimental medicine · 2024Review
- COVID-19 in immunocompromised patients after hematopoietic stem cell transplantation: a pilot study.Blood science (Baltimore, Md.) · 2024Article
- COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant.Cancers · 2024Article
- Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.British journal of haematology · 2023Article
- SARS-CoV-2 Infection, Hospitalization, and Mortality in Adults With and Without Cancer.JAMA network open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors.
Joaquín Martínez-LópezHematology Department, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, CNIO-ISCIII, CIBERONC, 28041 Madrid, Spain.ORCID 0000-0001-7908-0063
Javier De la CruzResearch Institute, Hospital Universitario 12 de Octubre, imas12, 28041 Madrid, Spain.
Rodrigo Gil-MansoHematology Department, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, CNIO-ISCIII, CIBERONC, 28041 Madrid, Spain.
Adrián AlegreHematology Department, Hospital Universitario de La Princesa, IIS-HUP, 28006 Madrid, Spain.ORCID 0000-0002-2423-822X
Javier OrtizHematology Department, Hospital Universitario de La Princesa, IIS-HUP, 28006 Madrid, Spain.ORCID 0000-0003-4945-9114
Pilar LlamasHematology Department, Hospital Fundación Jiménez Díaz, Health Research Institute IIS-FJD, 28040 Madrid, Spain.
Yolanda MartínezHematology Department, Hospital Fundación Jiménez Díaz, Health Research Institute IIS-FJD, 28040 Madrid, Spain.ORCID 0000-0003-1692-2248
José-Ángel Hernández-RivasHematology Department, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain.ORCID 0000-0003-4550-757X
Isabel González-GascónHematology Department, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain.ORCID 0000-0001-6329-1704
Celina BenaventeHematology Department, Hospital Clínico San Carlos, 28040 Madrid, Spain.
Pablo Estival MonteliuHematology Department, Hospital Clínico San Carlos, 28040 Madrid, Spain.
Víctor Jiménez-YusteHematology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.ORCID 0000-0003-3937-3499
Miguel CanalesHematology Department, Clínica Universidad de Navarra, 28027 Madrid, Spain.ORCID 0000-0002-6550-2621
Mariana BastosHematology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.ORCID 0000-0002-9431-4646
Mi KwonHematology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.ORCID 0000-0002-3855-7774
Susana ValencianoHematology Department, Hospital Universitario HM Sanchinarro, 28050 Madrid, Spain.
Marta Callejas-CharaviaHematology Department, Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Alcalá de Henares, 28805 Madrid, Spain.
Javier López-JiménezHematology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0002-2969-3002
Pilar HerreraHematology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0002-4118-7110
Rafael DuarteHematology Department, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Madrid, Spain.
Lucía Núñez Martín-BuitragoHematology Department, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Madrid, Spain.
Pedro Sanchez GodoyHematology Department, Hospital Universitario Severo Ochoa, 28911 Madrid, Spain.
Cristina Jacome YeroviHematology Department, Hospital Universitario Severo Ochoa, 28911 Madrid, Spain.
Pilar Martínez-BarrancoHematology Department, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain.
María García RoaHematology Department, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain.
Cristian Escolano EscobarHematology Department, Hospital Universitario de Getafe, 28905 Madrid, Spain.
Arturo MatillaHematology Department, Hospital Central de la Defensa Gómez Ulla, 28047 Madrid, Spain.ORCID 0000-0003-0902-1871
Belén Rosado SierraHematology Department, Hospital Universitario Rey Juan Carlos, Móstoles, 28933 Madrid, Spain.
María Concepción Aláez-UsónHematology Department, Hospital HLA Universitario Moncloa, 28027 Madrid, Spain.
Keina Quiroz-CervantesHematology Department, Hospital Universitario de Móstoles, 28935 Madrid, Spain.
Carmen Martínez-ChamorroHematology Department, Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón, 28223 Madrid, Spain.
Jaime Pérez-OteyzaHematology Department, Hospital Universitario HM Sanchinarro, 28050 Madrid, Spain.
Rafael Martos-MartinezHematology Department, Hospital Universitario General de Villalba, Villalba, 28400 Madrid, Spain.
Regina HerráezHematology Department, Hospital Universitario Infanta Sofía, San Sebastián de Los Reyes, 28702 Madrid, Spain.
Clara González-SantillanaHematology Department, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain.
Juan Francisco Del CampoHematology Department, Hospital Universitario del Henares, Coslada, 28822 Madrid, Spain.
Arancha AlonsoHematology Department, Hospital Ruber, 28006 Madrid, Spain.
Adolfo de la FuenteHematology Department, MD Anderson Cancer Center Madrid, 28033 Madrid, Spain.
Adriana PascualHematology Department, Hospital Universitario Infanta Elena, Valdemoro, 28340 Madrid, Spain.
Rosalía Bustelos-RodriguezHematology Department, Hospital Universitario del Sureste, Arganda del Rey, 28500 Madrid, Spain.
Ana SebrangoHematology Department, Hospital Universitario de Torrejón, 28850 Madrid, Spain.
Elena RuizHematology Department, Hospital Universitario del Tajo, Aranjuez, 28300 Madrid, Spain.
Eriel Alexis Marcheco-PupoHematology Department, Hospital Universitario Infanta Cristina, Parla, 28980 Madrid, Spain.
Carlos GrandeHematology Department, Clínica Universidad de Navarra, 28027 Madrid, Spain.
Ángel CedilloAsociación Madrileña de Hematología y Hemoterapia (AMHH), 28040 Madrid, Spain.
Carlos LumbrerasInternal Medicine Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Andrés Arroyo BareaHematology Department, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, CNIO-ISCIII, CIBERONC, 28041 Madrid, Spain.
José Manuel Casas-RojoInternal Medicine Department, Hospital Universitario Infanta Cristina, Parla, 28980 Madrid, Spain.ORCID 0000-0002-6649-4301
Maria CalbachoHematology Department, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, CNIO-ISCIII, CIBERONC, 28041 Madrid, Spain.
José Luis Diez-MartínHematology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.
Julio García-SuárezHematology Department, Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Alcalá de Henares, 28805 Madrid, Spain.
Asociación Madrileña de Hematología y Hemoterapia (AMHH)
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February-June 2020;
Indexed as
acute leukemiaCOVID-19hematological malignancieslymphomamultiple myelomaSARS-CoV-2
Identifiers
What OpenQuestion holds
Textfull text, public
LicenceCC BY
measurements read142
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.